|
AU2013203561A1
|
|
Vaccine immunotherapy
|
|
AU2012200672A1
|
|
"Vaccine immunotherapy for immune suppressed patients"
|
|
WO2012037551A2
|
|
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
CA2820202A1
|
|
Method of reversing immune suppression of langerhans cells
|
|
AU2010248761A1
|
|
Vaccine immunotherapy
|
|
EP2296704A1
|
|
Mechanism of action of primary cell derived biologic
|
|
AU2009244617A1
|
|
IRX-2 modified manufacturing process
|
|
AU2008329741A1
|
|
Method of increasing immunological effect
|
|
WO2005003295A2
|
|
Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
|
|
US7182942B2
|
|
Vaccine immunotherapy for immune suppressed patients
|
|
EP1446159A2
|
|
Immunotherapy for reversing immune suppression
|
|
CA2950109A1
|
|
Vaccine immunotherapy for immune suppressed patients
|
